Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The Agentic Era: Vertical Software’s New Growth Engine

    From automating entire workflows to unlocking trillions of dollars in new enterprise value, AI is transforming vertical software. Learn why industry-specific platforms are poised to lead the next wave of productivity and growth in the Agentic Era.

    Read more

  • Interviewing Investors: A Step-by-Step Guide for Business Owners

    The due diligence process is a two-way street—and business owners should perform detailed evaluations of potential partners.

    Read more

  • Data Centers: The Quiet Champion of Commercial Real Estate Growth

    AI and cloud computing are fueling explosive growth in data centers, quietly transforming them into commercial real estate’s next powerhouse sector. Firms that build on their existing expertise to manage these highly specialized facilities stand to capture meaningful, durable growth for years to come.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures